31 related articles for article (PubMed ID: 33058464)
1. Machine learning facilitated structural activity relationship approach for the discovery of novel inhibitors targeting EGFR.
Choudhary R; Walhekar V; Muthal A; Kumar D; Bagul C; Kulkarni R
J Biomol Struct Dyn; 2023; 41(22):12445-12463. PubMed ID: 36762704
[TBL] [Abstract][Full Text] [Related]
2. Using machine learning to decode animal communication.
Rutz C; Bronstein M; Raskin A; Vernes SC; Zacarian K; Blasi DE
Science; 2023 Jul; 381(6654):152-155. PubMed ID: 37440653
[TBL] [Abstract][Full Text] [Related]
3. A Novel Graph Neural Network Methodology to Investigate Dihydroorotate Dehydrogenase Inhibitors in Small Cell Lung Cancer.
Zhi HY; Zhao L; Lee CC; Chen CY
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33806898
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
5. Machine Learning, Molecular Docking, and Dynamics-Based Computational Identification of Potential Inhibitors against Lung Cancer.
Das AP; Mathur P; Agarwal SM
ACS Omega; 2024 Jan; 9(4):4528-4539. PubMed ID: 38313551
[TBL] [Abstract][Full Text] [Related]
6. Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC.
Lu J; Ji X; Liu X; Jiang Y; Li G; Fang P; Li W; Zuo A; Guo Z; Yang S; Ji Y; Lu D
Sci Rep; 2024 Jan; 14(1):446. PubMed ID: 38172228
[TBL] [Abstract][Full Text] [Related]
7. A systematic pipeline of protein structure selection for computer-aided drug discovery: A case study on T790M/L858R mutant EGFR structures.
Das AP; Nandekar P; Mathur P; Agarwal SM
Protein Sci; 2023 Sep; 32(9):e4740. PubMed ID: 37515373
[TBL] [Abstract][Full Text] [Related]
8. Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADMET, machine learning, molecular docking and a dynamics approach.
Agarwal SM; Nandekar P; Saini R
RSC Adv; 2022 Jun; 12(26):16779-16789. PubMed ID: 35754875
[TBL] [Abstract][Full Text] [Related]
9. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
10. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
11. TMLRpred: A machine learning classification model to distinguish reversible EGFR double mutant inhibitors.
Saini R; Fatima S; Agarwal SM
Chem Biol Drug Des; 2020 Sep; 96(3):921-930. PubMed ID: 33058464
[TBL] [Abstract][Full Text] [Related]
12. EGFRisopred: a machine learning-based classification model for identifying isoform-specific inhibitors against EGFR and HER2.
Saini R; Agarwal SM
Mol Divers; 2022 Jun; 26(3):1531-1543. PubMed ID: 34345964
[TBL] [Abstract][Full Text] [Related]
13. Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR.
Huo D; Wang H; Qin Z; Tian Y; Yan A
Mol Divers; 2022 Jun; 26(3):1715-1730. PubMed ID: 34636023
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity Relationship Study on Therapeutically Relevant EGFR Double Mutant Inhibitors.
Fatima S; Agarwal SM
Med Chem; 2020; 16(1):52-62. PubMed ID: 30727906
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
